Trial Profile
A Phase I Study of Avelumab, Palbociclib, and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 04 Dec 2023
Price :
$35
*
At a glance
- Drugs Avelumab (Primary) ; Cetuximab (Primary) ; Palbociclib (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions
- 29 Nov 2023 Planned End Date changed from 1 Jul 2023 to 1 Dec 2024.
- 01 Dec 2022 Results published in the Oral Oncology
- 16 Feb 2022 Planned End Date changed from 1 Jan 2022 to 1 Jul 2023.